Skip to main content
SpringerLink
Log in

Zielstruktur für neue Therapeutika

MikroRNA-92a-Hemmer für die Behandlung von Herz-Kreislauf-Erkrankungen

  • Fortbildung
  • Schwerpunkt Kardiologie
  • Published:
CardioVasc Aims and scope

MikroRNAs (miRNA) sind kurze, nicht kodierende RNAs, die die Regulation der Proteinsynthese auf mRNA-Ebene steuern. Die mikroRNA-92a (miR-92a) ist eine Ischämie-regulierte miRNA, deren Expression unter pathophysiologischen Bedingungen hochreguliert ist. Sie stellt eine interessante Zielstruktur für die Entwicklung von neuen Therapeutika zur Behandlung von Herzinfarkt- und Atherosklerosepatienten oder Wundheilungsstörungen dar.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Small EM, Olson EN. Pervasive roles of microRNAs in cardiovascular biology. Nature. 2011;469(7330):336–42

    Article  CAS  Google Scholar 

  2. Bonauer A, Boon RA, Dimmeler S. Vascular microRNAs. Curr Drug Targets. 2010;11(8):943–9

    Article  CAS  Google Scholar 

  3. Bonauer A, Carmona G, Iwasaki M et al. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science. 2009;324(5935):1710–3

    Article  CAS  Google Scholar 

  4. Loyer X, Potteaux S, Vion AC et al. Inhibition of microRNA-92a prevents endothelial dysfunction and atherosclerosis in mice. Circ Res. 2014;114(3):434–43

    Article  CAS  Google Scholar 

  5. Wu W, Xiao H, Laguna-Fernandez A et al. Flow-Dependent Regulation of Kruppel-Like Factor 2 Is Mediated by MicroRNA-92a. Circulation. 2011;124(5):633–41

    Article  CAS  Google Scholar 

  6. Fang Y, Davies PF. Site-specific microRNA-92a regulation of Kruppel-like factors 4 and 2 in atherosusceptible endothelium. Arterioscler Thromb Vasc Biol. 2012;32(4):979–87

    Article  CAS  Google Scholar 

  7. Zhang B, Zhou M, Li C et al. MicroRNA-92a inhibition attenuates hypoxia/reoxygenation-induced myocardiocyte apoptosis by targeting Smad7. PLoS One. 2014;9(6):e100298

    Article  Google Scholar 

  8. Lai L, Song Y, Liu Y et al. MicroRNA-92a negatively regulates Toll-like receptor (TLR)-triggered inflammatory response in macrophages by targeting MKK4 kinase. J Biol Chem. 2013;288(11):7956–67

    Article  CAS  Google Scholar 

  9. Taurino C, Miller WH, McBride MW et al. Gene expression profiling in whole blood of patients with coronary artery disease. Clin Sci (Lond). 2010;119(8):335–43

    Article  CAS  Google Scholar 

  10. Fichtlscherer S, De Rosa S, Fox H et al. Circulating microRNAs in patients with coronary artery disease. Circ Res. 2010;107(5):677–84

    Article  CAS  Google Scholar 

  11. Lucas T, Schäfer F, Müller P et al. Light-inducible antimiR-92a as a therapeutic strategy to promote skin repair in healing-impaired diabetic mice. Nat Commun. 2017;8:15162

    Article  Google Scholar 

  12. Krützfeldt J, Rajewsky N, Braich R et al. Silencing of microRNAs in vivo with “antagomirs”. Nature. 2005;438(7068):685–9

    Article  Google Scholar 

  13. Lennox KA, Behlke MA. A direct comparison of anti-microRNA oligonucleotide potency. Pharm Res. 2010;27(9):1788–99

    Article  CAS  Google Scholar 

  14. Bellera N, Barba I, Rodriguez-Sinovas A et al. Single intracoronary injection of encapsulated antagomir-92a promotes angiogenesis and prevents adverse infarct remodeling. J Am Heart Assoc. 2014;3(5):e000946

    Article  Google Scholar 

  15. Hinkel R, Penzkofer D, Zühlke S et al. Inhibition of microRNA-92a protects against ischemia/reperfusion injury in a large-animal model. Circulation. 2013;128(10):1066–75

    Article  CAS  Google Scholar 

  16. Iaconetti C, Polimeni A, Sorrentino S et al. Inhibition of miR-92a increases endothelial proliferation and migration in vitro as well as reduces neointimal proliferation in vivo after vascular injury. Basic Res Cardiol. 2012;107(5):296

    Article  Google Scholar 

  17. Daniel JM, Penzkofer D, Teske R et al. Inhibition of miR-92a improves re-endothelialization and prevents neointima formation following vascular injury. Cardiovasc Res. 2014;103(4):564–72

    Article  CAS  Google Scholar 

  18. Shang F, Wang SC, Hsu CY et al. MicroRNA-92a Mediates Endothelial Dysfunction in CKD. J Am Soc Nephrol. 2017;28(11):3251–61

    Article  Google Scholar 

  19. Henique C, Bollée G, Loyer X et al. Genetic and pharmacological inhibition of microRNA-92a maintains podocyte cell cycle quiescence and limits crescentic glomerulonephritis. Nat Commun. 2017;8(1):1829

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für kardiovaskuläre Regeneration, Zentrum für Molekulare Medizin, J.W. Goethe Universität Frankfurt am Main, Theodor-Stern-Kai 7, 60590, Frankfurt, Deutschland

    Tina Lucas &  Stefanie Dimmeler

  2. Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), Berlin, Deutschland

    Tina Lucas &  Stefanie Dimmeler

Authors
  1. Tina Lucas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stefanie Dimmeler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stefanie Dimmeler.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lucas, T., Dimmeler, S. MikroRNA-92a-Hemmer für die Behandlung von Herz-Kreislauf-Erkrankungen. CV 18, 47–51 (2018). https://doi.org/10.1007/s15027-018-1342-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15027-018-1342-y

Search

Navigation